Podcast appearances and mentions of jeffrey nau

Today's podcast shines the spotlight on the front of the eye, focusing new treatments and approaches to dry eye disease, blepharitis, and Sjogren's Syndrome, to name a few.Kelly Nichols, OD, PhD, dean of the University of Alabama at Birmingham School of Optometry, guides a panel of four clinical and industry experts through a robust conversation on ocular surface disease.They start by sharing their optimism around new treatments and awareness initiatives. Jeffrey Nau, PhD, president of the newly formed Viatris Eye Care Division, said progress is inching along now, but “it's only a matter of time until we have a massive uplift that will completely change the way we look at ocular surface disease.”In late 2021, the FDA approved Tyrvaya, the first nasal spray for dry eye disease. Researchers continue to evaluate treatments and diagnostics from multiple angles. Physicians continue to tailor their approaches to better educate, diagnose, and treat ocular surface disease patients. What's next?Listen to the podcast today to hear the panelists discuss these and other topics, including:What excites you about current and emerging eye care innovations?What's your approach for both new and returning dry eye patients?What's your typical patient intake workflow?How much time do you spend educating dry eye patients?How important are companion diagnostics in ocular surface disease?[Press Play to Listen]

Identifying MDs and ODs is but one of many activities involved in developing a commercial launch strategy. To execute that launch according to targets requires strong data, effective messaging, thoughtful strategy, and luck. According to a ZS analysis, out of 30 emerging pharma first launches from 2019 through 2021, only four met expectations.At the OIS XII panel “Maximizing OD/MD Market Potential and How to Achieve Commercial Success With a New Product,”a group of commercialization experts discussed what it takes to get a product to market and meet analysts' expectations. Robert J. Dempsey, MBA, CEO and president of AsclepiX Therapeutics, moderated the panel. Tarsus Pharmaceuticals, for example, is launching TP-03, which would be the first approved treatment for Demodex blepharitis, a disease of Demodex mites infesting the eyelids. It affects about 25 million people. Tarsus Chief Commercial Officer Aziz Mottiwala said education and thoughtful patient identification are key elements of Tarsus' strategy.  Education also plays a role when meeting with payers. Oyster Point Pharma president and CEO Jeffrey Nau, PhD, MMS, said ophthalmology companies must present a strong scientific story well before a product goes to market. Tony Tipton, COO of Xequel Bio, agreed, noting companies must also stay strong in their belief in the product and its value. Listen to the podcast today to hear this  expert panel discuss:How they approach conversations among payers, pharmacy benefit managers, and MDs and ODs.How key opinion leader relationships have shifted over the past 10 years.Precommercial strategies for a new company with a new launch.Strategies for navigating the payer space.Obstacles and opportunities in pre-launch. Key performance indicators for measuring the early success of a commercial launch.Also participating on the panel was Carey Powers, global head of corporate marketing, Avellino Lab USA.Click “play” to listen.

The Food and Drug Administration approved Tyrvaya (varenicline solution), a multidose nasal spray, to treat signs and symptoms of dry eye disease, about a year ago. Jeffrey Nau, PhD, MMS, CEO of Oyster Point Pharma, sat down with OIS Podcast host Paul Karpecki, OD, FAAO, to discuss the launch and his learnings over the year that was.  Since then, about 62,000 Tyrvaya prescriptions have been written. It's the first and only nasal spray designed for dry eye relief. Dr. Nau says refills and persistence numbers are strong.  Dr. Karpecki said he's noticed similar results in his own practice. Of patients who received a Tyrvaya sample, the requests for prescriptions and refills have been dramatic. While Oyster Point has release positive post hoc data of Tyrvaya, Dr. Nau said there's still a learning curve to overcome. Physicians simply aren't used to prescribing a nasal spray for dry eye. Will that change in 2023? Listen to the podcast today to hear Dr. Nau and Dr. Karpecki discuss: How Oyster Point launched Tyrvaya after running Phase III trials at the peak of the pandemic.What Dr. Nau has learned from the Tyrvaya launch over the past year.The surprises that occurred during the Tyrvaya launch and how Oyster Point overcame them.How Oyster Point navigates uncontrollable events such as COVID-19 and the rocky economy.Oyster Point's commercialization strategy for 2023—both for Tyrvaya and the rest of its pipeline. Click “play” to listen now.

Innovation can sometimes be counterintuitive, as in the case with Tyrvaya, a drug approved in 2021 for the signs and symptoms of dry eye disease that is a nasal spray. And how does that make sense? Well, it makes sense because Tyrvaya ®, a cholinergic agonist to treat the underlying, and sometimes debilitating disease. Hear Dr. Jeffrey Nau, ophthalmology expert and CEO of Oyster Point explain…

Dr. Jeffrey Nau, CEO of Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company discusses the company's lead candidate, OC-01, a nasal spray being developed to treat the signs and symptoms of dry eye disease (DED). Current treatment options are limited to eye drops, which can be difficult and uncomfortable to self-administer. The FDA accepted their New Drug Application for OC-01, which was supported by safety and efficacy results from clinical trials in over 1,000 patients with mild, moderate, or severe symptoms of DED. The U.S. launch of OC-01 nasal spray is planned for the fourth quarter of 2021, if approved by the FDA. Jeffrey Nau, PhD, MMS, President and Chief Executive Officer. Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that, Jeff was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Jeff has helped raise more than $250 million in equity for innovative startups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He holds numerous patents and peer-reviewed publications. Jeff has a Ph.D. in Public Health and Epidemiology from Walden University, a M.S. in Medical Science from MCP Hahnemann School of Medicine, and a B.S. in Biology from Stony Brook University.

Host Ehsan Sadri, MD, is joined by Jeffrey Nau, PhD, who shares insights from a career in ophthalmology that has led to his current role as the CEO of publicly traded Oyster Point Pharma. In this interview, Jeff addresses some of the recent setbacks from COVID-19, conducting business virtually, different indications the company plans to address, and opportunities that lie ahead.

Leveraging neuroscience to discover and develop novel therapies to treat ocular surface diseases For the show notes, full transcript, links, and resources please visit us at show link:  https://bit.ly/2BrdYqu

With more than $100 million raised in venture capital and three late-stage clinical programs, Oyster Point Pharma is getting a lot done in a short amount of time. In this podcast, CEO and president Jeffrey Nau reveals how the company is working so quickly and ponders what the next major milestone might be.

Jeffrey Nau is CEO of Oyster Point Pharma, a clinical stage pharmaceutical company focused on developing commercial therapies dealing with parasympathetic pathways. In a climate where oncology and rare diseases get most of the attention, Nau talks about what it’s like working on diseases that don’t get the same press, like dry eye, which is the focus of their current Phase 2 clinical trial. How this impacts raising capital and other bumps in the road he has come across. Having extensive experience with raising startup money, Nau outlines some best practices when it comes to funding.

With Oyster Point Pharma announcing results from the Phase IIb PEARL study, company president and CEO Jeffrey Nau, PhD, talks with OIS Podcast about what the findings mean for OC-02, a nicotinic acetylcholine receptor agonist the company is developing to treat the signs and symptoms of dry eye disease. The study met both primary endpoints by showing a statistically significant improvement in signs and symptoms compared with control. Top-line data from the study will be presented this weekend at the American-European Congress of Ophthalmic Surgery Summer Symposium in Deer Valley, UT. OC-02 is delivered as a nasal spray and stimulates the trigeminal parasympathetic pathway to activate the glands responsible for producing the eye’s natural tear film.

Hear the latest from OIS events as the OIS Podcast connects with Tom Frinzi and Joseph Boorady, the new leadership at Johnson & Johnson Vision. Next, CEO Jeffrey Nau introduces Oyster Point to OIS while Rob Thornhill, CEO of Tear Film Innovations, explains his company's treatment for Meibomian Gland Disorder.

Join us for another installment of the Graphic Novice Book Club, as we are joined by Jeffrey Nau, of the History of Bad Ideas podcast, to discuss the Watchmen.